Cargando…

The emergence of drug resistance in tumours: a characteristic which may be exploited therapeutically.

Detalles Bibliográficos
Autor principal:	Tattersall, M. H.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1973
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2008802/ https://www.ncbi.nlm.nih.gov/pubmed/4576563

Ejemplares similares

Rapid fluorometric detection of drug resistant tumour cells.
por: deFazio, A., et al.
Publicado: (1985)

The Accidents Which May Happen to Ovarian Cystic Tumours
Publicado: (1908)

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
por: Brown, J. M.
Publicado: (1993)

Dominant negative biologics normalise the tumour necrosis factor (TNF-α) induced angiogenesis which exploits the Mycobacterium tuberculosis dissemination
por: Davuluri, Kusuma Sai, et al.
Publicado: (2023)

A Tumour in Which Both Sarcomatous and Carcinomatous Characteristics Are Present
por: Iyengar, K. R. Sitarama
Publicado: (1936)

The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study.
por: Saunders, M. I., et al.
Publicado: (1982)

Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia
por: Huang, Xianbo, et al.
Publicado: (2018)

Mechanisms by which the intestinal microbiota affects gastrointestinal tumours and therapeutic effects
por: He, Jikai, et al.
Publicado: (2023)

The Exploitation of Liposomes in the Inhibition of Autophagy to Defeat Drug Resistance
por: Condello, Maria, et al.
Publicado: (2020)

Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro.
por: Huschtscha, L. I., et al.
Publicado: (1996)

Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
por: Brown, J. M.
Publicado: (1998)

Enhanced nanoparticle delivery exploiting tumour-responsive formulations
por: Bennie, Lindsey A., et al.
Publicado: (2018)

On the Nature and Structural Characteristics of Cancer, and of Those Morbid Growths Which May Be Confounded with It
Publicado: (1840)

On the Nature and Structural Characteristics of Cancer, and of Those Morbid Growths Which May Be Confounded with It
Publicado: (1840)

On the Nature and Structural Characteristics of Cancer, and of Those Morbid Growths Which May Be Confounded with It
Publicado: (1840)

Community perspectives on the extent to which transactional sex is viewed as sexual exploitation in Central Uganda
por: Kyegombe, N., et al.
Publicado: (2020)

Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug.
por: Cummings, J., et al.
Publicado: (1986)

Macropinocytosis Exploitation by Cancers and Cancer Therapeutics
por: Ha, Kevin D., et al.
Publicado: (2016)

Exploiting tumour addiction with a serine and glycine-free diet
por: Amelio, Ivano, et al.
Publicado: (2017)

Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model
por: Christowitz, Claudia, et al.
Publicado: (2019)

Ovarian tumour xenografts in the study of the biology of human epithelial ovarian cancer.
por: Friedlander, M. L., et al.
Publicado: (1985)

Plateau-phase cultures: an experimental model for identifying drugs which are bioactivated within the microenvironment of solid tumours.
por: Phillips, R. M., et al.
Publicado: (1997)

The ROCKs on which tumour cells thrive
por: Wilkinson, Simon, et al.
Publicado: (2016)

Risk factors that may be driving the emergence of drug resistance in tuberculosis patients treated in Yangon, Myanmar
por: Khan, Mishal S., et al.
Publicado: (2017)

Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development
por: Feng, Jie, et al.
Publicado: (2019)

Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis
por: Nicolai, S, et al.
Publicado: (2015)

Dysregulation of Macropinocytosis Processes in Glioblastomas May Be Exploited to Increase Intracellular Anti-Cancer Drug Levels: The Example of Temozolomide
por: Colin, Margaux, et al.
Publicado: (2019)

Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
por: Davis, Lorraine N., et al.
Publicado: (2021)

Evidence of the Mechanism by Which Polyomaviruses Exploit the Extracellular Vesicle Delivery System during Infection
por: Giannecchini, Simone
Publicado: (2020)

Targeting the Tumour Vasculature: Exploitation of Low Oxygenation and Sensitivity to NOS Inhibition by Treatment with a Hypoxic Cytotoxin
por: Baker, Jennifer H. E., et al.
Publicado: (2013)

Exploiting inflammation for therapeutic gain in pancreatic cancer
por: Steele, C W, et al.
Publicado: (2013)

Apoptosis pathways and their therapeutic exploitation in pancreatic cancer
por: Fulda, Simone
Publicado: (2009)

The mechanisms by which hyperbaric oxygen and carbogen improve tumour oxygenation.
por: Brizel, D. M., et al.
Publicado: (1995)

The critical incident inventory: characteristics of incidents which affect emergency medical technicians and paramedics
por: Halpern, Janice, et al.
Publicado: (2012)

Development of drug resistance in a murine mammary tumour.
por: McMillan, T. J., et al.
Publicado: (1985)

Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein.
por: Cole, S. P., et al.
Publicado: (1989)

The role of PARP in DNA repair and its therapeutic exploitation
por: Javle, M, et al.
Publicado: (2011)

Extracellular RNAs in Bacterial Infections: From Emerging Key Players on Host-Pathogen Interactions to Exploitable Biomarkers and Therapeutic Targets
por: Pita, Tiago, et al.
Publicado: (2020)

Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance
por: Lee, Sung Woo, et al.
Publicado: (2017)

Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies
por: Hattinger, Claudia Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_94udc2a0am3jn4nfo4o7n28clt